Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness
- 29 August 2018
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 156, 322-339
Abstract
No abstract availableKeywords
Funding Information
- Council of Scientific and Industrial Research, India
- Council of Scientific and Industrial Research, India
- University Grants Commission
- University Grants Committee
This publication has 57 references indexed in Scilit:
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatmentCell Death & Disease, 2013
- Determining Mammosphere-Forming Potential: Application of the Limiting Dilution AnalysisJournal of Mammary Gland Biology and Neoplasia, 2012
- The Role of Autophagy in Cancer: Therapeutic ImplicationsMolecular Cancer Therapeutics, 2011
- Pharmacogenomics and cancer stem cells: a changing landscape?Trends in Pharmacological Sciences, 2011
- Triple-Negative Breast CancerThe Cancer Journal, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- Heterogeneity in Cancer: Cancer Stem Cells versus Clonal EvolutionCell, 2009
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003